These people practically can lead normal lives, like anyone managing a chronic illness
La esclerosis múltiple, durante décadas sinónimo de deterioro inevitable y dependencia, está siendo redefinida por la medicina en Albacete. Cerca de 800 pacientes reciben hoy atención especializada en la provincia, la mayoría con terapias de alta eficacia que reducen los brotes en torno a un 80%, transformando un diagnóstico que antes condenaba a la silla de ruedas en una enfermedad crónica manejable. En un momento en que la ciencia devuelve el futuro a quienes más lo necesitan —adultos jóvenes en plena construcción de sus vidas—, el equipo neurológico del Complejo Hospitalario de Albacete trabaja para formalizar una unidad multidisciplinar que consolide ese progreso.
- Una enfermedad que históricamente llegaba tarde al diagnóstico y peor al tratamiento ahora se detecta antes y se frena con mayor eficacia, aunque el número de casos registrados sigue creciendo: de 700 a 800 pacientes en apenas un año.
- El 70% de los pacientes ya recibe fármacos de alta eficacia que reducen los síntomas de los brotes aproximadamente un 80%, convirtiendo lo que antes era una sentencia de discapacidad progresiva en una condición compatible con una vida casi normal.
- La enfermedad golpea principalmente entre los 20 y los 40 años, con predominio femenino, pero los neurólogos advierten una tendencia inédita: casos que debutan entre los 50 y los 60 años, cuya causa aún no se comprende.
- Síntomas como alteraciones visuales, pérdida de fuerza o problemas de equilibrio que persisten más de 24 horas exigen atención neurológica urgente, y la concienciación creciente entre pacientes y médicos de atención primaria está reduciendo los casos que escapan al diagnóstico.
- El equipo liderado por la doctora María Palao prepara la acreditación de una unidad multidisciplinar formal, un paso que no es solo administrativo sino una apuesta por la atención estandarizada y el seguimiento sistemático a largo plazo.
La esclerosis múltiple lleva décadas ganándose el apodo de «la enfermedad de las mil caras»: sus síntomas son tan variados y a veces tan sutiles —problemas de visión, debilidad, pérdida de equilibrio— que durante años el diagnóstico llegaba tarde, cuando el daño ya estaba hecho. Ese patrón está cambiando en Albacete, donde la clínica especializada en enfermedades desmielinizantes inflamatorias del sistema nervioso central atiende hoy a cerca de 800 pacientes, un centenar más que hace apenas un año. La mejora en las técnicas de imagen y una mayor concienciación tanto en pacientes como en médicos de cabecera explican en parte ese aumento, aunque los especialistas no descartan que haya también un incremento real de la incidencia.
Lo que ha cambiado de forma más radical es el pronóstico. La doctora María Palao, que lidera el equipo junto a Eva María Fernández Díaz, Carlos Romero Sánchez y Julia Gracia Gil, lo resume con claridad: donde antes un adulto joven diagnosticado con esclerosis múltiple podía esperar una discapacidad progresiva y, con frecuencia, dependencia de una silla de ruedas, hoy la mayoría de los pacientes lleva una vida esencialmente normal. El 70% recibe ya fármacos de alta eficacia que reducen los brotes en torno a un 80%, reescribiendo la historia natural de la enfermedad.
La enfermedad sigue afectando sobre todo a personas de entre 20 y 40 años, con un pico alrededor de los 30, y muestra un claro predominio femenino. Pero algo nuevo está apareciendo en las consultas: pacientes que desarrollan la enfermedad entre los 50 y los 60 años, un fenómeno antes excepcional que los neurólogos observan con atención sin haber encontrado aún una explicación.
El equipo trabaja ahora para obtener la acreditación como unidad multidisciplinar formal, un reconocimiento que va más allá de lo burocrático: supone un compromiso con la atención protocolizada, la formación continua y el seguimiento a largo plazo que permite a los pacientes vivir como desean vivir.
Multiple sclerosis earned its nickname—the disease of a thousand faces—because it wears so many different masks. A patient might experience vision problems one week, weakness in the limbs the next, balance issues the week after. Some symptoms are so mild or vague that people don't think to see a doctor. Others are so unusual that doctors miss them entirely. For decades, this diagnostic fog meant that by the time someone got a confirmed diagnosis, the disease had often already done significant damage.
That pattern is changing in Albacete. The neurologists who staff the specialized clinic for inflammatory demyelinating diseases of the central nervous system now have better tools—more precise diagnostic criteria, faster imaging, clearer pathways to detection. The result is visible in their patient rolls: nearly 800 people with multiple sclerosis are now under active care at the Integrated Care Management of Albacete, up from around 700 just a year earlier. The clinic, led by physicians including Dr. María Palao, is preparing documentation for accreditation as a formal multidisciplinary unit, a recognition of how central this work has become to the region's healthcare.
What matters most, though, is not the rising numbers but what those numbers represent: a fundamental shift in what multiple sclerosis means for someone who receives the diagnosis. The vast majority of the clinic's patients are now on disease-modifying therapies. Roughly 70 percent are taking high-efficacy medications—drugs that have rewritten the natural history of the disease. These treatments reduce relapse symptoms by approximately 80 percent. Dr. Palao was direct about the transformation: decades ago, a young person diagnosed with MS faced a prognosis of progressive disability, likely wheelchair dependence, a life increasingly constrained. Today, she said, the reality is fundamentally different. People with MS can now live essentially normal lives, managing their condition much as someone might manage any other chronic illness.
The disease still strikes hardest during the prime working and family-building years. Most cases debut between ages 20 and 40, with the peak typically around 30. The relapsing-remitting form—where symptoms flare and then improve—is most common in this age group. Progressive forms tend to emerge a bit later, between 30 and 40. But something unexpected has begun appearing in recent years: patients developing MS in their 50s and even 60s, a pattern that was once rare enough to be almost unheard of. The neurologists are watching this shift carefully, though the cause remains unclear.
Certain warning signs should send someone to a neurologist immediately. Vision problems—particularly difficulty distinguishing colors or pain when moving the eyes—can signal optic neuritis, an inflammation of the optic nerve that is characteristic of MS. Unexplained loss of strength or sensation anywhere in the body warrants urgent evaluation. Balance problems, too. The clinic's physicians emphasize that any of these symptoms lasting more than 24 hours, especially after ruling out infection or other temporary causes, demands specialist attention.
Dr. Palao acknowledged that the rising case count likely reflects multiple factors. Better access to imaging technology means more accurate diagnoses. Improved awareness among both patients and primary care doctors means fewer cases slip through undiagnosed. But there may also be a genuine increase in incidence—the reasons for which remain unclear. What is clear is that the disease shows a strong female predominance, consistent with other autoimmune conditions, though this pattern does not hold for all the other inflammatory neurological diseases the clinic treats.
The team doing this work includes Eva María Fernández Díaz, María Palao Rico, Carlos Romero Sánchez, and Julia Gracia Gil. They are building something that did not exist before: a formal, accredited center of expertise for a disease that was once a death sentence and is now, for many patients, a manageable condition. The accreditation they are pursuing is not merely bureaucratic. It represents a commitment to standardized care, ongoing education, and the kind of systematic follow-up that allows people to live the lives they want to live.
Notable Quotes
Thanks to the therapeutic arsenal we have today, disease progression is no longer synonymous with disability for a young person receiving this diagnosis— Dr. María Palao
We have increasingly better access to imaging, which allows us to reach a more accurate diagnosis, and perhaps that is why we detect more patients with this neurodegenerative disease— Dr. María Palao
The Hearth Conversation Another angle on the story
Why does MS get called the disease of a thousand faces?
Because it genuinely can present almost any neurological symptom. Vision problems, weakness, numbness, balance issues—sometimes all in the same patient, sometimes just one. That variability is what made diagnosis so hard for so long. People would see a doctor about one symptom, get told it was probably nothing, and by the time someone connected the dots, years had passed.
And that's changing because of better imaging?
Partly. Better imaging helps. But it's also better diagnostic criteria—neurologists now know what to look for, what patterns matter. A patient comes in with optic neuritis, and we can now say with confidence whether this is MS or something else. That speed matters enormously.
The article mentions 70 percent of patients on high-efficacy drugs. What does that actually mean for someone's life?
It means the difference between planning a career and planning around disability. These drugs reduce relapses by about 80 percent. A relapse used to mean weeks or months of lost function. Now many patients go years without a significant flare. They can work, have families, make long-term plans.
But the disease is still striking younger people?
Yes. The typical patient is in their 20s or 30s when symptoms start. That's the hardest time to get this diagnosis—you're building a life, and suddenly you're managing a chronic illness. The drugs have made that manageable in ways it wasn't before.
You mentioned late-onset cases in your 50s and 60s. Is that new?
It's unusual enough that the neurologists are paying close attention. It used to be rare. Now they're seeing it regularly. No one is sure why yet.
What should someone watch for?
Vision changes—especially trouble with colors or pain when you move your eyes. Unexplained weakness or numbness anywhere. Balance problems. If any of that lasts more than a day, see a neurologist. Don't wait.